Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study-Reference-Cited by-同舟云学术

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

Published:2011-04-28 Issue:6 Volume:153 Page:729-740
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Richardson Paul G.,Chanan-Khan Asher A.,Lonial Sagar,Krishnan Amrita Y.,Carroll Michael P.,Alsina Melissa,Albitar Maher,Berman David,Messina Marianne,Anderson Kenneth C.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08664.x/fullpdf

Reference31 articles.

1. Clinically relevant end points and new drug approvals for myeloma;Anderson;Leukemia,2008

2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;New England Journal of Medicine,1996

3. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study;Bagatell;Clinical Cancer Research,2007

4. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies;Banerji;Journal of Clinical Oncology,2005

5. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Blade;British Journal of Haematology,1998

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction;International Journal of Molecular Sciences;2024-08-16

2. Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer;International Journal of Molecular Sciences;2024-02-08

3. Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells;Cell Death Discovery;2023-10-13

4. Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain;Cancers;2022-12-08

5. Novel NRF2 ‐activated cancer treatments utilizing synthetic lethality;IUBMB Life;2022-10-18